| Wissenschaftl. Titel | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination with Daratumumab SC and Pomalidomide (Tal-DP) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd) or Talquetamab SC and Daratumumab SC (Tal-D), in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma (RLRMM) who Have Received at Least 2 Prior Lines of Therapy (MonumenTAL-3) |
| Erkrankung |
Haema:
Multiples Myelom:
Zweitlinie oder später
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (MZ) Weiterführende Informationen (EudraCT) |
erstellt 10.11.2023 Data entry III CCP
geändert 19.04.2024 Data entry III CCP